中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 3
Mar.  2023
Turn off MathJax
Article Contents

Association between primary sclerosing cholangitis and the risk of colorectal cancer: A two-sample Mendelian randomization study

DOI: 10.3969/j.issn.1001-5256.2023.03.013
Research funding:

Scientific Research Fund project of Yunnan Education Department (2022J0691)

More Information
  • Corresponding author: DU Ning, 489676174@qq.com (ORCID: 0000-0003-0517-2234)
  • Received Date: 2022-08-03
  • Accepted Date: 2022-10-01
  • Published Date: 2023-03-20
  •   Objective  To investigate the association between primary sclerosing cholangitis (PSC) and colorectal cancer (CRC) by using two-sample Mendelian randomization (TSMR).  Methods  The single nucleotide polymorphism (SNP) data associated with PSC and CRC were obtained from Finland Biobank and UK Biobank, respectively. A secondary data analysis was performed for all pooled data based on genome-wide association studies to select the genetic loci closely associated with PSC as instrumental variables, and TSMR was conducted by seven methods, i.e., Egger regression in Mendelian randomization, weighted median, inverse variance weighted (IVW) random effects model, maximum likelihood, linear weighted median, IVW radial method, and IVW fixed effects model. Odds ratio (OR) value was used to evaluate the causal relationship between PSC and the risk of CRC.  Results  There was a positive causal relationship between gene predicted PSC and CRC, and with the IVW fixed effects model as an example, genetically determined patients with PSC could increase the risk of CRC (OR=1.002 243, 95% confidence interval: 1.001 319-1.003 167). TSMR results showed no heterogeneity (P=0.87) or horizontal pleiotropy (P=0.95). The three instrumental variables selected for PSC were strong instrumental variables (F=11.86).  Conclusion  TSMR shows the genetic evidence for the association between PSC and the risk of CRC. Regardless of the presence or absence of inflammatory bowel disease, active enteroscopy screening among patients with PSC may help with the early identification and timely intervention of CRC.

     

  • loading
  • [1]
    KARLSEN TH, FOLSERAAS T, THORBURN D, et al. Primary sclerosing cholangitis - a comprehensive review[J]. J Hepatol, 2017, 67(6): 1298-1323. DOI: 10.1016/j.jhep.2017.07.022.
    [2]
    VESTERHUS M, KARLSEN TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities[J]. J Gastroenterol, 2020, 55(6): 588-614. DOI: 10.1007/s00535-020-01681-z.
    [3]
    HENSON JB, HELZBERG JH, MUIR AJ. Patient-predicted outcomes are associated with quality of life in patients with primary sclerosing cholangitis[J]. Dig Dis Sci, 2022, 67(12): 5483-5492. DOI: 10.1007/s10620-022-07482-z.
    [4]
    de KRIJGER M, CARVALHO B, RAUSCH C, et al. Genetic profiling of colorectal carcinomas of patients with primary sclerosing cholangitis and inflammatory bowel disease[J]. Inflamm Bowel Dis, 2022, 28(9): 1309-1320. DOI: 10.1093/ibd/izac087.
    [5]
    ABBAS N, QURAISHI MN, TRIVEDI P. Emerging drugs for the treatment of primary sclerosing cholangitis[J]. Curr Opin Pharmacol, 2022, 62: 23-35. DOI: 10.1016/j.coph.2021.11.003.
    [6]
    NASSER-GHODSI N, MARA K, WATT KD. De novo colorectal and pancreatic cancer in liver-transplant recipients: identifying the higher-risk populations[J]. Hepatology, 2021, 74(2): 1003-1013. DOI: 10.1002/hep.31731.
    [7]
    SINGH S, EDAKKANAMBETH VARAYIL J, LOFTUS EV Jr, et al. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis[J]. Liver Transpl, 2013, 19(12): 1361-1369. DOI: 10.1002/lt.23741.
    [8]
    BRADEN B, HALLIDAY J, ARYASINGHA S, et al. Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2012, 10(3): 303-308. DOI: 10.1016/j.cgh.2011.10.020.
    [9]
    XIE Y, CHEN X, DENG M, et al. Causal linkage between inflammatory bowel disease and primary sclerosing cholangitis: a two-sample mendelian randomization analysis[J]. Front Genet, 2021, 12: 649376. DOI: 10.3389/fgene.2021.649376.
    [10]
    LUNDBERG BÅVE A, BERGQUIST A, BOTTAI M, et al. Increased risk of cancer in patients with primary sclerosing cholangitis[J]. Hepatol Int, 2021, 15(5): 1174-1182. DOI: 10.1007/s12072-021-10214-6.
    [11]
    FUNG BM, LINDOR KD, TABIBIAN JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies[J]. World J Gastroenterol, 2019, 25(6): 659-671. DOI: 10.3748/wjg.v25.i6.659.
    [12]
    ROMPIANESI G, RAVIKUMAR R, JOSE S, et al. Incidence and outcome of colorectal cancer in liver transplant recipients: A national, multicentre analysis on 8115 patients[J]. Liver Int, 2019, 39(2): 353-360. DOI: 10.1111/liv.13947.
    [13]
    KOMAKI Y, KOMAKI F, MICIC D, et al. Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis[J]. Gastrointest Endosc, 2017, 86(1): 93-104.e5. DOI: 10.1016/j.gie.2016.12.009.
    [14]
    GOSSARD AA, GORES GJ. Primary sclerosing cholangitis: what the gastroenterologist and hepatologist needs to know[J]. Clin Liver Dis, 2017, 21(4): 725-737. DOI: 10.1016/j.cld.2017.06.004.
    [15]
    SHAH SC, TEN HOVE JR, CASTANEDA D, et al. High risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease[J]. Clin Gastroenterol Hepatol, 2018, 16(7): 1106-1113.e3. DOI: 10.1016/j.cgh.2018.01.023.
    [16]
    HORSLEY-SILVA JL, RODRIGUEZ EA, FRANCO DL, et al. An update on cancer risk and surveillance in primary sclerosing cholangitis[J]. Liver Int, 2017, 37(8): 1103-1109. DOI: 10.1111/liv.13354.
    [17]
    TRIVEDI PJ, CROTHERS H, MYTTON J, et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age[J]. Gastroenterology, 2020, 159(3): 915-928. DOI: 10.1053/j.gastro.2020.05.049.
    [18]
    LOFTUS EV, SANDBORN WJ, TREMAINE WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis[J]. Gastroenterology, 1996, 110(2): 432-440. DOI: 10.1053/gast.1996.v110.pm8566590.
    [19]
    ADAMOWICZ M, STUKAN I, MILKIEWICZ P, et al. Modulation of mismatch repair and the SOCS1/p53 axis by microRNA-155 in the colon of patients with primary sclerosing cholangitis[J]. Int J Mol Sci, 2022, 23(9): 4905. DOI: 10.3390/ijms23094905.
    [20]
    VESTERHUS M, KARLSEN TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities[J]. J Gastroenterol, 2020, 55(6): 588-614. DOI: 10.1007/s00535-020-01681-z.
    [21]
    SAFFIOTI F, GURUSAMY KS, HAWKINS N, et al. Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis[J]. Cochrane Database Syst Rev, 2017, 3(3): CD011343. DOI: 10.1002/14651858.CD011343.pub2.
    [22]
    JI SG, JURAN BD, MUCHA S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease[J]. Nat Genet, 2017, 49(2): 269-273. DOI: 10.1038/ng.3745.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(2)

    Article Metrics

    Article views (800) PDF downloads(162) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return